Soleno Therapeutics, Inc.

NASDAQ:SLNOHealthcare · Biotechnology

Mkt Cap-

Float-

Shares O/S-

Inst Own-

Dilution

Mkt Cap-

Float-

O/S-

Inst Own-

Dilution

NASDAQ:SLNO

MCap-

Float-

O/S-

Inst Own-

Dilution

Historical Data

Date	Open	High	Low	Close	Volume

Key Metrics

Market Cap--

Enterprise Value--

P/E Ratio--

Est. Net Cash/Share--

Institutional Ownership--

SectorHealthcare

IndustryBiotechnology

ExchangeNASDAQ

Country

IPO DateNov 13, 2014

Shares Outstanding-

Float--

Company Overview

Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.

Leadership

Andrew Sinclair

Director

Anish Bhatnagar

Chairman, President & CEO

Anish Bhatnagar, M.D.

Chief Executive Officer and Chairman of the Board

Birgitte Volck

Director

Employees

115

Country

Sector

Healthcare

Website

soleno.life

Analyst Coverage

ConsensusBuy

Price Target

No price targets available

Ratings Distribution

BUY

HOLD

SELL

TOTAL13

Insider Trading

Insider	Title	Type	Shares	Value	Date
Yen Kristen	SEE REMARKS	Withholding/Transfer	37.6K	--	May 18, 2026
Sinclair Andrew	Director	Withholding/Transfer	10.5K	--	May 18, 2026
Norrett Kevin	Chief Business Officer	Withholding/Transfer	17.8K	--	May 18, 2026
Volck Birgitte	Director	Withholding/Transfer	17.5K	--	May 18, 2026
Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	Withholding/Transfer	583.7K	--	May 18, 2026
Joshi Manher	Chief Development Officer	Withholding/Transfer	72.3K	--	May 18, 2026

Shareholders

Institutional

(7)

Insiderⓘ

(2)

5%+ Owners

(0)

Unattributed (incl. retail)ⓘ

Top Shareholders

Name	Shares	%	Source
JANUS HENDERSON GROUP PLC	7.1M	--	13F
VANGUARD GROUP INC	3.1M	--	13F
BlackRock, Inc. · filed Jul 2025	2.8M	5.5%	13G
Avoro Capital Advisors LLC · filed May 2026	2.3M	4.5%	13G
JANUS HENDERSON GROUP PLC · also on 13F· may incl. warrants· filed May 2026	1.2M	2.3%	13G
T. Rowe Price Associates, Inc. · filed May 2026	1.0M	2.0%	13G
FMR LLC · filed May 2026	193.0K	0.4%	13G
Mackaness James H CHIEF FINANCIAL OFFICER	131.8K	--	FORM 4
Militia Capital Partners, LP	35.0K	--	13F
MidWestOne Financial Group, Inc.	21.8K	--	13F